The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 13, 2021

Filed:

Jun. 29, 2016
Applicants:

The Arizona Board of Regents on Behalf of the University of Arizona, Tucson, AZ (US);

Joslin Diabetes Center, Inc., Boston, MA (US);

Inventors:

Michael S. Kuhns, Tucson, AZ (US);

Thomas Serwold, Boston, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/74 (2006.01); C07K 14/725 (2006.01); C07K 14/705 (2006.01); A61K 35/17 (2015.01); C12N 5/0783 (2010.01); C12N 9/12 (2006.01);
U.S. Cl.
CPC ...
C07K 14/70539 (2013.01); A61K 35/17 (2013.01); C07K 14/705 (2013.01); C07K 14/7051 (2013.01); C12N 5/0636 (2013.01); C12N 9/12 (2013.01); C12Y 207/10002 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/74 (2013.01);
Abstract

Chimeric receptors featuring major histocompatibility molecules grafted onto T cell receptor molecules and surrogate co-receptors featuring cell surface receptor ligands fused with signaling molecule domains. The chimeric receptors can be used to redirect cells, altering their specificity. T cells expressing chimeric receptors may bind to ICRs of target T cells for which their chimeric receptors are specific. Surrogate co-receptors may be used to help enhance TCR-CD3 signaling as part of this modular receptor system. The chimeric receptors and surrogate coreceptors may be used to help eliminate autoreactive T cells or program T cells to desired effector functions.


Find Patent Forward Citations

Loading…